Nicholas Short, MD
Enriched profileAssociate Professor, Department of Leukemia, Division of Cancer Medicine (also Associate Program Director, Department of Leukemia, 2025-present) · The University of Texas MD Anderson Cancer Center
Nicholas Short is Associate Professor, Department of Leukemia, Division of Cancer Medicine (also Associate Program Director, Department of Leukemia, 2025-present) at The University of Texas MD Anderson Cancer Center. OpenAlex indexes 1,096 publications with 17,540 citations (h-index 66); ClinicalTrials.gov lists 15 registered studies with this person as an investigator.
Data verified 17 Aug 2026
Overview
Updated 27 Aug 2026
Nicholas James Short, MD, is Associate Professor, Department of Leukemia, Division of Cancer Medicine (also Associate Program Director, Department of Leukemia, 2025-present) at The University of Texas MD Anderson Cancer Center, Houston, TX. The public record shows 1,096 publications with 17,540 citations (h-index 66), centered on Acute Myeloid Leukemia Research, Chronic Myeloid Leukemia Treatments, Acute Lymphoblastic Leukemia research. It also documents an investigator role on 15 registered clinical trials, industry payments reported by 21 companies, 1 NIH-funded awards (2026–2026).
- Most recent indexed publication: 2026 · Blood cancer journal
- Top research focus: Acute Myeloid Leukemia Research
- 15 registered trials on ClinicalTrials.gov
- Open Payments reporting from 21 companies
Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 200 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 311.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 27 Aug 2026
Listed as an investigator on 15 registered studies on ClinicalTrials.gov. The most recent:
Industry payments
Updated 27 Aug 2026
21 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Adaptive Biotechnologies CorporationProgram year20256 payments$19,696openpaymentsdata.cms.gov ↗
- Amgen Inc.Program year20253 payments$17,132openpaymentsdata.cms.gov ↗
- Merck Sharp & Dohme LLCProgram year20256 payments$13,031openpaymentsdata.cms.gov ↗
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
47.9%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor27.4%Valacyclovir100%Part D≥14 patientsFluoroquinolone Antibacterial20.5%Levofloxacin100%Part D≥11 patientsCancer & immunology
32.9%Kinase inhibitor16.4%Sprycel100%Part D<11 patientsBCL-2 Inhibitor16.4%Venclexta100%Part D<11 patientsMetabolism & gastrointestinal
19.2%Corticosteroid19.2%Prednisone100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 27 Aug 2026
1 NIH research award on record, funded 2026–2026 per NIH RePORTER. The latest:
- Advancing TGFβ-Resistant CAR-NK Cell Therapy for Acute Myeloid Leukemia
University of Tx Md Anderson Can Ctr
FY2026$387,156R01CA315771
Publications
Updated 27 Aug 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Inotuzumab ozogamicin therapy for measurable residual disease in adult acute lymphoblastic leukemia.
Blood cancer journal
Article2026 - Long-Term Outcomes of Azacitidine, Venetoclax and Gilteritinib in Newly Diagnosed FLT3-Mutated AML.
Blood advances
Article2026
Most-cited works
by citation count (OpenAlex)- 01Acute myeloid leukaemia782 citations2018
- 02
- 03
- 04
- 05
Network
Updated 27 Aug 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 27 Aug 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/nicholas-short-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - LinkedIn
linkedin.com/in/nicholas-short-30559b8a
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗ - Other
faculty.mdanderson.org/profiles/nicholas_short.html
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
Mentions by others
where others cite or feature them- Other
vjhemonc.com/speaker/nicholas-short
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →vjhemonc.com ↗ - X / Twitter
x.com/MDAndersonNews/status/1837867872682398031
- X / Twitter
Nicholas Short and crediting him for leading the research at MD Anderson
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 27 Aug 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- M.S. in Biomedical Sciences
UT MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences
2022verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
Editorial & leadership roles
journal and society appointments- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
Secondary affiliations
appointments beyond the home institution- Assistant/Associate Professor listing corroborated via Elsevier Pure research profile
Department of Leukemia, MD Anderson Cancer Center
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mdanderson.elsevierpure.com ↗ - Physician
MD Anderson Leukemia Center clinical team (patient-facing practice listing)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mdanderson.org ↗
Media & interviews
press, podcasts and appearances- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →vjhemonc.com ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →cancernetwork.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Hagop Kantarjian, MD
The University of Texas MD Anderson Cancer Center
Gabriel Hortobagyi, MD
The University of Texas MD Anderson Cancer Center
Jaffer Ajani, MD
The University of Texas MD Anderson Cancer Center
Funda Meric-Bernstam, MD
The University of Texas MD Anderson Cancer Center